InNexus Biotechnology Inc.

DENVER - Key Data are New Releases for the Company Building on Milestones with Recent FDA Meetings and Technology Discoveries - DXL625 monoclonal antibodies appear to be superior to commercial-stage antibodies in their ability to attach and deplete NHL in late stage pre-clinical studies, according to research conducted at InNexus Biotechnology Inc.

SCOTTSDALE, Arizona - Additional Presentations Underscore Potency, Binding Capabilities for Antibody Pipeline And Novel Technologies - InNexus Biotechnology Inc.